PubMed · 2425668
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
J W Jorgenson. 1986. Electrophoresis.. https://doi.org/10.1021/ac00298a001
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
In glioblastoma (GBM), the most frequent and lethal brain tumor, therapies suppressing recurrently altered signaling pathways failed to extend survival. However, in patient subsets, specific genetic lesions can confer sensitivity to targeted agents. By exploiting an integrated model based on patient-derived stem-like cells, faithfully recapitulating the original GBMs in vitro and in vivo, here, we identify a human GBM subset (∼9% of all GBMs) characterized by ERBB3 overexpression and nuclear accumulation. ERBB3 overexpression is driven by inheritable promoter methylation or post-transcriptional silencing of the oncosuppressor miR-205 and sustains the malignant phenotype. Overexpressed ERBB3 behaves as a specific signaling platform for fibroblast growth factor receptor (FGFR), driving PI3K/AKT/mTOR pathway hyperactivation, and overall metabolic upregulation. As a result, ERBB3 inhibition by specific antibodies is lethal for GBM stem-like cells and xenotransplants. These findings highlight a subset of patients eligible for ERBB3-targeted therapy.
Several groups have reported that during apoptosis, cytochrome c is released from the mitochondria into the cytosol, but we have found that in apoptotic cells the cytochrome appears to remain with the mitochondria. In hopes of reconciling these findings, we compared the results obtained from cells disrupted by our method (nitrogen cavitation) with those obtained using the cell-disruption method employed by others (homogenization). We observed that at 2 h, cytochrome c levels in apoptotic cytosols from homogenized cells exceeded control levels, whereas cytochrome c levels in apoptotic cytosols from cavitated cells were similar to control. Outer membranes of homogenized mitochondria appeared damaged because the mitochondria had become permeable to cytochrome c, whereas outer membranes of cavitated mitochondria excluded the cytochrome. 4 h after Fas ligation, both cavitated and homogenized mitochondria had released small amounts of cytochrome c into the cytosol, whereas after 6 h the cytochrome had disappeared from the cell lysate. We believe that the differences between our results and those reported by others were due to 1) our examining the cells after a short (2 h) incubation with the anti-Fas antibody, and 2) our use of nitrogen cavitation instead of homogenization to disrupt the cells.
Human CD2 is a 50-55-kDa cell surface receptor specifically expressed on the surface of T lymphocytes and NK cells. Stimulation of human peripheral blood T cells with mitogenic pairs of anti-CD2 monoclonal antibodies (mAbs) is sufficient to induce interleukin-2 production and T cell proliferation in the absence of an antigen-specific signal through the T cell receptor. CD2 has been shown previously to associate physically with the Src family protein-tyrosine kinases p56(lck) and p59(fyn). We now report that stimulation of T cells with mitogenic pairs of anti-CD2 mAbs enhanced the association of the Fyn polypeptide with the CD2 complex, whereas stimulation with single anti-CD2 mAb had minimal effect. Using glutathione S-transferase (GST) fusion proteins, we found that CD2 bound to the Src homology (SH) 3 domain of Fyn. Interestingly, the CD2-Fyn association was negatively regulated by the Fyn SH2 domain; CD2 bound poorly to GST fusion proteins expressing both the SH2 and SH3 domains of Fyn. However, the inhibitory effect of the Fyn SH2 domain on binding of the Fyn SH3 domain to CD2 was relieved by peptides containing a phosphorylated YEEI sequence that bound directly to the Fyn SH2 domain. In addition, we found that the ability of the Fyn SH2 domain to precipitate tyrosine-phosphorylated proteins, including the CD3zeta chain, was enhanced after T cell stimulation with mitogenic pairs of CD2 mAbs. Finally, overexpression of a mutated Fyn molecule, in which the ability of the Fyn SH2 domain to bind phosphotyrosine-containing proteins was abrogated, inhibited CD2-induced transcriptional activation of the nuclear factor of activated T cells (NFAT), suggesting a functional involvement of the Fyn SH2 domain in CD2-induced T cell signaling. We thus propose that stimulation through the CD2 receptor leads to the tyrosine phosphorylation of intracellular proteins, including CD3zeta itself, which in turn bind to the Fyn-SH2 domain, allowing the direct association of the Fyn SH3 domain with CD2 and the initiation of downstream signaling events.